CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
filgrastim +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002505
NCT00002505Phase 2Completed
CompareCT.gov

RANDOMIZED PHASE II TRIAL OF AUTOLOGOUS TUMOR CELL VACCINE

Hoag Memorial Hospital Presbyterian·interventional·Posted Jun 28, 2004·Updated May 12, 2011

In Brief

A Phase 2 clinical trial evaluating filgrastim, recombinant interferon gamma, and 1 other intervention for Unspecified Adult Solid Tumor, Protocol Specific. Completed, across 4 sites.

Detailed Summary

RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsCancer Biotherapy Research Group

Timeline

Phase 2CompletedFinished
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 28, 2004
Enrollment StartAug 1, 1992
Primary CompletionAug 1, 2002
Study CompletionMay 1, 2006
TodayJul 2, 2026
Enrollment to primary: 10 yearsPosted 22.0 years ago

Interventions

filgrastimbiological

recombinant interferon gammabiological

tumor cell lysate vaccine therapybiological